Who are Cabergoline tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Standard of Care Oral antipsychotics, combination with dopamine agonist cabergoline, Intramuscular olanzapine, aripiprazole, OBR, Flupentixol melitracen tablets, aripiprazole long acting injectable formulation.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cabergoline-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Cabergoline tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cabergoline tablets (Cabergoline tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine D2 receptor agonist. Area: Endocrinology.

phase 3 Dopamine D2 receptor agonist Dopamine D2 receptor Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Cabergoline tablets (Cabergoline tablets) — Changchun GeneScience Pharmaceutical Co., Ltd.. Cabergoline is a dopamine D2 receptor agonist that inhibits prolactin secretion from the anterior pituitary gland.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Cabergoline tablets TARGET	Cabergoline tablets	Changchun GeneScience Pharmaceutical Co., Ltd.	phase 3	Dopamine D2 receptor agonist	Dopamine D2 receptor
Standard of Care Oral antipsychotics	Standard of Care Oral antipsychotics	University of Utah	marketed	Antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor
combination with dopamine agonist cabergoline	combination with dopamine agonist cabergoline	Ludwig-Maximilians - University of Munich	marketed	Dopamine agonist	Dopamine D2 receptor
Intramuscular olanzapine, aripiprazole	Intramuscular olanzapine, aripiprazole	Veterans Medical Research Foundation	marketed	Atypical antipsychotic	Dopamine D2 receptor; serotonin 5-HT2A receptor (olanzapine); dopamine D2 partial agonist (aripiprazole)
OBR	OBR	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Atypical antipsychotic (depot formulation)	Dopamine D2 receptor (partial agonist)
Flupentixol melitracen tablets	Flupentixol melitracen tablets	Peking University Third Hospital	marketed	Typical antipsychotic + tricyclic antidepressant combination	Dopamine D2 receptor (flupentixol); norepinephrine and serotonin transporters (melitracen)
aripiprazole long acting injectable formulation	aripiprazole long acting injectable formulation	Vanguard Research Group	marketed	Atypical antipsychotic (dopamine partial agonist)	Dopamine D2 receptor, Dopamine D3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine D2 receptor agonist class)

Changchun GeneScience Pharmaceutical Co., Ltd. · 2 drugs in this class
Fertility Center of Las Vegas · 1 drug in this class
University of North Carolina, Chapel Hill · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cabergoline tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/cabergoline-tablets. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing